Daratumumab is a medicine used to treat a type of cancer called multiple myeloma, which affects a type of white blood cell called plasma cells. It's a type of drug known as a monoclonal antibody, which means it's designed to target specific proteins on cancer cells and help the body's immune system fight the cancer.
Imagine your body is like a big city, and inside it, there are lots of different cells with different jobs. One type of cell, called a plasma cell, helps your body fight infections by making antibodies. But sometimes, these plasma cells turn into cancer cells and start growing out of control, causing problems like multiple myeloma.
That's where daratumumab comes in. It's like a superhero that targets a protein called CD38, which is found on the surface of multiple myeloma cells. Daratumumab latches onto CD38 and flags the cancer cells for destruction by the immune system. It's like putting a spotlight on the bad guys and calling in reinforcements to take them down.
Doctors usually give daratumumab as an infusion, which means it's delivered directly into a vein through an IV. The frequency and dosage of the infusions can vary depending on factors like the stage of the cancer and how well the patient responds to treatment.
Like many cancer treatments, daratumumab can cause side effects. Some common ones include infusion reactions, which can cause symptoms like fever, chills, and low blood pressure. Other side effects may include tiredness, nausea, diarrhea, and low levels of certain blood cells.
Despite these potential side effects, daratumumab has been shown to be effective in treating multiple myeloma, both on its own and in combination with other cancer treatments. In fact, it's become an important part of standard treatment for many patients with multiple myeloma, particularly those who have relapsed or whose cancer hasn't responded to other treatments.
Before starting treatment with daratumumab, patients should discuss their medical history and any other medications they're taking with their healthcare provider to ensure it's safe and appropriate for them. It's also important to communicate openly with your doctor about any side effects you experience during treatment so they can be managed effectively.
In summary, daratumumab is a targeted therapy that helps the immune system fight multiple myeloma by targeting a protein called CD38 on cancer cells. While it can cause side effects, it's an important treatment option for many patients with multiple myeloma and has the potential to improve outcomes and quality of life.
Have any queries, book a consultation with our Oncology Clinical Specialist
top of page
₹500.00Price
bottom of page